We posit that this occurrence may be akin to the “fellow-eye effect,” wherein small-molecule anti-VEGF drugs, known for their high permeability, achieve elevated intraocular drug concentrations in both eyes upon bilateral administration, leading to a concurrent diminution of macular edema and improvement in vision in both eyes (22–24). The gene discussed is VEGFA; the disease is macular retinal edema.